MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial

Disease Sites:

Multiple Myeloma

Staging:

Phase II

Age Group:

Adults

Therapies:

Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics, Therapy (NOS)

Drugs:

Bortezomib (BTZ), Daratumumab, Dexamethasone, Lenalidomide, Melphalan, Teclistamab

Principal Investigator(s):

Baljevic, Muhamed

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

01-16-2025

Trial Type:

Treatment

Protocol ID:

VICC-ITPCL23014

National Clinical Trial ID:

NCT05231629

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available